- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02905604
Magnetic Stimulation of the Brain in Schizophrenia or Depression (MA-SCH-DEP)
Magnetic Stimulation of the Brain in Schizophrenia or Depression: A Randomized, Double Blind, Sham Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Schizophrenia or Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double blind parallel randomized sham controlled trial. The intervention is intermittent theta-burst stimulation (iTBS), which is rTMS with theta burst frequency with 2400 pulses/day in two sessions at 90% of resting motor threshold intensity over the DMPFC, given in ten days on week days (10 treatment days must be completed within a maximum of 21 days). Stratified (depression and schizophrenia diagnosis) block randomization will be used for treatment allocation to active or sham side of the stimulation coil.
Patients will be referred from their regular psychiatric care facilities. At the screening visit the patient will be assessed if fulfilling all inclusion and none of the exclusion criteria. At the baseline visit thorough psychiatric, cognitive and neurophysiological examination will be performed. The latter include investigation of cortical excitability with paired-pulse TMS, mismatch negativity (MMN, a measure of aberrant stimulus detection), startle-response, habituation, electrodermal activity (EDA), near-infrared spectroscopy (NIRS), 24 hour actigraphy and heart rate registration.
During 10 week days the participants will receive a daily rTMS (or sham) treatment. On the day after last rTMS treatment the examinations performed at the baseline visit will be repeated. Four weeks after baseline there is a shorter visit to follow-up symptoms and functioning. At the end of this visit the blinding is unmasked and patients who have received sham rTMS will be offered active treatment in an open-phase. After the four weeks follow-up there are two additional and identical visits at 10 and 26 weeks after start of treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 751 85
- Department of neuroscience, psychiatry, unit for Brain Stimulation and psychiatric clinical trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of schizophrenia spectrum disorders or uni- or bipolar depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.)
- negative symptoms with anhedonia and avolition: ≤40 points on the The Motivation and Pleasure Scale-Self-Report (MAP-SR)
- unchanged medication the past month
- provision of signed informed consent form
Exclusion Criteria:
- epilepsy
- conductive ferromagnetic or other magnetic sensitive metals implanted in the head or within 30 cm of the treatment coil
- implanted device that is activated or controlled in any way by physiological signals
- implanted mediation pumps
- intracardiac lines, even when removed
- addiction (illicit drugs or alcohol) and pregnancy
- any condition that seriously increases the risk of non-compliance or loss of follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dmPFC iTBS
Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors.
The rTMS is given in 20 trains to the left and right dmPFC, respectively.
Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz.
The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off.
After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day.
Treatment is delivered daily at 10 week days.
|
2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
Other Names:
|
Sham Comparator: dmPFC Sham iTBS
A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered.
The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient.
Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
|
Sham iTBS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change of total score on the Clinical Assessment Interview for Negative Symptoms (CAINS).
Time Frame: From baseline to day after last treatment, i.e. 14-21 days after baseline
|
From baseline to day after last treatment, i.e. 14-21 days after baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change of total score on the CAINS
Time Frame: From baseline to four weeks after baseline.
|
From baseline to four weeks after baseline.
|
Change in Clinical Global Impression (CGI) score
Time Frame: From baseline to four weeks after baseline.
|
From baseline to four weeks after baseline.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Bodén, Ph.D, MD, Uppsala University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MA-SCH-DEP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Study Data/Documents
-
Study Protocol
Information comments: Updated investigational plan can be requested from the Swedish medical products agency
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on dmPFC iTBS
-
Taipei Veterans General Hospital, TaiwanCompletedTreatment Resistant DepressionTaiwan
-
Shanghai Mental Health CenterRecruiting
-
The University of Texas Health Science Center,...CompletedCocaine Use DisorderUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)Not yet recruitingCocaine Use DisorderUnited States
-
Stanford UniversityRecruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityNot yet recruitingTreatment Resistant DepressionUnited States
-
University Health Network, TorontoUnknownMajor Depression | Borderline Personality DisorderCanada
-
Central South UniversityRecruitingSuicidal Ideation | Suicide and Self-harm | Non Suicidal Self InjuryChina
-
Changping LaboratoryChina Rehabilitation Research CenterRecruiting
-
Central South UniversityRecruitingBipolar Depression | Major Depressive DisorderChina